Pembrolizumab Approved for Esophageal or Gastroesophageal Cancer

Am J Nurs. 2021 Jul 1;121(7):25. doi: 10.1097/01.NAJ.0000758492.37647.3a.

Abstract

Pembrolizumab (Keytruda) has been approved to treat metastatic or locally advanced esophageal or gastroesophageal junction cancer. It is used in combination with platinum- and fluoropyrimidine-based chemotherapy.

Publication types

  • News

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antineoplastic Agents, Immunological / administration & dosage*
  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols
  • Esophageal Neoplasms / drug therapy*
  • Humans
  • Stomach Neoplasms / drug therapy*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • pembrolizumab